An observational study in Colorectal Cancer, sponsored by Newcastle University. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2019-07-02.
Sponsored by Newcastle University · Observational
Worldwide, colorectal cancer is the 3rd most common cancer; risk increases with age and is modified by lifestyle factors notably diet, physical activity and obesity. The BORICC Follow-Up (BFU) Study is a 12+ year follow-up of participants recruited to the Biomarkers of Risk of Colon Cancer (BORICC) Study. This longitudinal study will investigate associations between ageing and lifestyle factors and a panel of molecular biomarkers linked with colorectal cancer risk.
The BORICC Follow-Up (BFU) Study builds on the findings from the BORICC Study where the investigators observed associations between age and nutritional factors, including selenium and folate, and biomarkers of colorectal health.
The BFU Study will investigate the relationships between ageing (12+ years) and such biomarkers longitudinally. It is anticipated that the project will produce novel data on (i) changes in biomarkers of colorectal cancer risk with age and (ii) the effects of obesity and lifestyle factors on biomarkers of colorectal cancer risk. These biomarkers include differentially expressed proteins, DNA methylation markers and inflammation markers.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's enrollment of 47 is below the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Newcastle University is the lead sponsor of 59 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who took part in the BORICC Study at baseline (2005/06) will be invited to participate in the BFU Study. This will include both participants recruited to the BORICC1 arm (healthy participants) and those recruited to the BORICC2 arm, with a prior history of polyps.
Exclusion Criteria:
Participants recruited to the healthy arm of the BORICC Study (BORICC1) at baseline.
Participants recruited to the polyp arm of the BORICC Study (BORICC2) at baseline, with a prior history of polyps.
Faecal calprotectin concentrations (marker of local inflammation)
Time frame: 12 years (on average)
Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation)
Time frame: 12 years (on average)
Gut microbiota (analysed in stool samples)
Abundance and diversity of the gut microbiota assessed in stool samples
Time frame: 12 years (on average)
Faecal short-chain fatty acid concentrations
Concentrations and proportions of short-chain fatty acids e.g. acetate, propionate and butyrate
Time frame: 12 years (on average)
DNA methylation in rectal mucosal biopsies(% methylation)
Target gene and global methylation (LINE-1) in rectal mucosal biopsies
Time frame: 12 years (on average)
Target gene expression in rectal mucosal biopsies
Expression of genes related to inflammation and the WNT signalling pathway in rectal mucosal biopsies
Time frame: 12 years (on average)
microRNA expression in rectal mucosal biopsies
Expression of microRNAs in rectal mucosal biopsies
Time frame: 12 years (on average)
Colonic crypt cell proliferative state
Total number and distribution of proliferating cells in rectal mucosal crypts
Time frame: 12 years (on average)
Colonic crypt cell dimensions
Height (length) and width rectal mucosal crypts
Time frame: 12 years (on average)
Markers of mitochondrial function and structure in rectal mucosal biopsies
Markers of mitochondrial function and structure in rectal mucosal biopsies such as oxidative phosphorylation proteins, namely complex I and IV
Time frame: 12 years (on average)
Parathyroid hormone in plasma
Time frame: 12 years (on average)
25-hydroxy vitamin D concentrations in serum
Time frame: 12 years (on average)
Vitamin B12 concentrations in serum
Time frame: 12 years (on average)
Folate concentrations in serum
Time frame: 12 years (on average)
Triglycerides in plasma
Time frame: 12 years (on average)
HDL cholesterol in plasma
Time frame: 12 years (on average)
LDL cholesterol in plasma
Time frame: 12 years (on average)
Total cholesterol in plasma
Time frame: 12 years (on average)
Glucose in plasma
Time frame: 12 years (on average)
HbA1c in whole blood
Time frame: 12 years (on average)
Timed-up and go test time
Time frame: 12 years (on average)
Hand grip strength using dynamometer
Time frame: 12 years (on average)
Heel bone density using Achilles heel ultrasound device
Time frame: 12 years (on average)
Body weight in kg
Time frame: 12 years (on average)
BMI in kg/m2 (calculated from height and weight)
Time frame: 12 years (on average)
Height in cm
Time frame: 12 years (on average)
Body fat percentage
Measured using Tanita Bioimpedance scales
Time frame: 12 years (on average)
Habitual dietary intake assessed using Food Frequency Questionnaire
Time frame: 12 years (on average)
Physical activity levels assessed using Lifestyle Questionnaire
Time frame: 12 years (on average)
Physical activity levels assessed using accelerometer
Time frame: 12 years (on average)
Sedentary behaviour assessed using Lifestyle Questionnaire
Time frame: 12 years (on average)
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Newcastle University